<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Burkitt's <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e>) is characterized by translocation of the MYC gene to an immunoglobulin locus </plain></SENT>
<SENT sid="1" pm="."><plain>Transgenic mouse models have been used to study the molecular changes that are necessary to bypass <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> suppression in the presence of translocated MYC </plain></SENT>
<SENT sid="2" pm="."><plain>Inactivation of the p53 pathway is a major step to <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> formation in mouse models that is also seen in human disease </plain></SENT>
<SENT sid="3" pm="."><plain>Human <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e> is often highly associated with Epstein-Barr virus (EBV) </plain></SENT>
<SENT sid="4" pm="."><plain>The EBV latency protein latent membrane protein 2A (LMP2A) is known to promote B cell survival by affecting levels of pro-survival factors </plain></SENT>
<SENT sid="5" pm="."><plain>Using LMP2A transgenic mouse models, we have identified a novel mechanism that permits <z:e sem="disease" ids="C0598766" disease_type="Neoplastic Process" abbrv="">lymphomagenesis</z:e> in the presence of an intact p53 pathway </plain></SENT>
<SENT sid="6" pm="."><plain>This work uncovers a contribution of EBV to molecular events that have documented importance in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e> pathogenesis, and may underlie the poorly understood link between EBV and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e> </plain></SENT>
</text></document>